Search Results - "Hungria V"

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors: Hungria, V. Robak, P. Hus, M. et al.

Source: New England Journal of Medicine. 8/1/2024, Vol. 391 Issue 5, p393-407. 15p.

Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.

Authors: Hungria, V. Crusoé, E. Maiolino, A. et al.

Source: Annals of Hematology. Jan2016, Vol. 95 Issue 2, p271-278. 8p.

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Authors: Hungria, V. (Vania)

URL: https://hdl.handle.net/10171/68022

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Authors: Costa, L. J. Bahlis, N. J. Perrot, A. et al.

Source: New England Journal of Medicine. 2/19/2026, Vol. 394 Issue 8, p739-752. 14p.

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Authors: Dimopoulos, M. A. Voorhees, P. M. Schjesvold, F. et al.

Source: New England Journal of Medicine. 5/8/2025, Vol. 392 Issue 18, p1777-1788. 12p.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Authors: Kastritis, E. Palladini, G. Minnema, M. C. et al.

Source: New England Journal of Medicine. 7/1/2021, Vol. 385 Issue 1, p46-58. 13p.

International Myeloma Working Group recommendations for global myeloma care.

Authors: Ludwig, H Miguel, J S Dimopoulos, M A et al.

Source: Leukemia (08876924). May2014, Vol. 28 Issue 5, p981-992. 12p.

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid†.

Authors: Vadhan-Raj, S. von Moos, R. Fallowfield, L. J. et al.

Source: Annals of Oncology. Dec2012, Vol. 23 Issue 12, p3045-3051. 7p.

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Authors: Parmar G Capra M Seguro F et al.

Source: Blood cancer journal [Blood Cancer J] 2025 Dec 27; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2025 Dec 27.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.

Authors: Souto Filho JTD Cantadori LO Crusoe EQ et al.

Source: Blood cancer journal [Blood Cancer J] 2025 Dec 06; Vol. 15 (1), pp. 212. Date of Electronic Publication: 2025 Dec 06.

Publication Type: Journal Article; Meta-Analysis; Network Meta-Analysis; Systematic Review

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

Authors: Bahlis NJ Zonder J Karlin L et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Dec; Vol. 66 (14), pp. 2685-2696. Date of Electronic Publication: 2025 Oct 03.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Authors: Dimopoulos MA Schjesvold F Fu C et al.

Corporate Authors: Dimopoulos MA Schjesvold F Fu C et al.

Source: Lancet (London, England) [Lancet] 2026 Jun 14. Date of Electronic Publication: 2026 Jun 14.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Authors: Mina R Beksac M Rodríguez-Otero P et al.

Corporate Authors: Mina R Beksac M Rodríguez-Otero P et al.

Source: The New England journal of medicine [N Engl J Med] 2026 Jun 13. Date of Electronic Publication: 2026 Jun 13.

Publication Type: Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

Authors: Zweegman S Facon T Hungria V et al.

Source: Blood advances [Blood Adv] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Brazilian consensus recommendations on the diagnosis and treatment of light chain amyloidosis.

Authors: Garibaldi PMM Souto Filho JTD de Magalhães Filho RJP et al.

Source: Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2026 Jun 02; Vol. 48 (3), pp. 106482. Date of Electronic Publication: 2026 Jun 02.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Editora Ltda Country of Publication: Brazil NLM ID: 101725732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2531-1387 (Electronic) Linking ISSN: 25311379 NLM ISO Abbreviation: Hematol Transfus Cell Ther

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Authors: Touzeau C Mina R Quach H et al.

Corporate Authors: Touzeau C Mina R Quach H et al.

Source: The New England journal of medicine [N Engl J Med] 2026 May 29. Date of Electronic Publication: 2026 May 29.

Publication Type: Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Authors: Kastritis E Palladini G Minnema MC et al.

Source: Blood [Blood] 2026 May 12. Date of Electronic Publication: 2026 May 12.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis.

Authors: Puig N Leleu X Lee HC et al.

Source: European journal of haematology [Eur J Haematol] 2026 Apr; Vol. 116 (4), pp. 458-470. Date of Electronic Publication: 2026 Jan 13.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

Authors: Las Casas PHFDC Marco-Ayala J Lefkou EE et al.

Source: British journal of haematology [Br J Haematol] 2026 Apr; Vol. 208 (4), pp. 1454-1457. Date of Electronic Publication: 2026 Feb 01.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE; In Process

Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era.

Authors: Hungria V Pinto Neto JV Garibaldi PMM et al.

Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2025 Apr; Vol. 25 (4), pp. e200-e209. Date of Electronic Publication: 2024 Dec 12.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE